# Zhrnutie informácií o kožných karcinómoch

## Typy karcinómov
* **Cutaneous squamous cell carcinoma (cSCC)**
* **Basal cell carcinoma**
* **Melanoma**

### Pozadie
* **Keranocytové karcinómy**:
    * Basal cell carcinoma: 75-80%
    * cSCC: 20%

## Analýza expresie génov a bunková anotácia

### Diferenciálna expresia
* **Basal KCs** (KRT15+, KRT14+), 
* **Differentiating KCs** (PKP1+, KRT10+), 
* **Dysplastic KCs** (S100A8+, S100A9+), 
* **KC interferon** (IFI27+), 
* **KC cornified** (SBSN+, KRT2+, DSC1+) 
* **KC hair** (combination of KRT6B+, KRT17+, KRT16+, KRT5+)

### Anotácia
* **Level 1**: endothelial cells, fibroblasts, melanocytes, keratinocytes, immune cell types
* **Level 2**: immune cell types = B cell, Plasma, CD14+ Mono, DC, Langerhans cells (LC) , NK, Macrophages, T cells
* **Level 3**: DC = (DC1DC2), LC = (LC, Ki67+ LC), NK = (CD15+ NK, CD16- NK), Mac = (CD169+ Mac, CX3CR1+ Mac, INF+ Mac, TREM2+ Mac), T cell = (CD4+ Tcm, CD8+ Tem, NKT, Tref, CD8+ Tcm, CD8+ Tem)


### Identifikácia rakovinových buniek
* Integrating gene signatures and inferred copy number variation to identify cancer keratinocyte (KC) cells 
Cancer cell 
    * abnormal polyploidy based on CNV analysis 
    * high cancer module scores as calculated for genes that were upregulated in tumour compared to normal tissues
* **82,6%** klasifikovaných rakovinových buniek bolo medzi **dysplastickými KCs**, čo ich robí pravdepodobnými rakovinovými bunkami.

## Zmeny v bunkovom zložení
Overall shifts in cellular composition between non-cancer and cancer skin samples revealed by scRNAseq data
* **Fibroblast** proportions were consistently higher in melanoma and cSCC-BCC than in non-cancer tissue
* The increased presence of both the **lymphoid** (i.e. T, B and NK cells) and **myeloid** (i.e. monocytes, macrophages and dendritic cells) in malignant skin matched the elevated expression of immune gene signature depicted by the core gene suite analysis 
* the **basal** and **differentiating** KCs were more prominent in healthy skin, whereas dysplastic and IFN KCs were enriched in cSCC samples


## Porovnanie cSCC a melanómu

Comparison cSCC and melanoma
* **Enriched genes in cSCC compared to melanomas**: Myc targets, E2F pathways, G2M pathways, mTOR
    * PTCH2 upregulated in KC cancers signaling and DNA repair pathways
* **Enriched genes in melanocyte lesions compared to cSCC** : KRAS pathway, EMT pathway, IL-2/STAT5 pathway, and UV responses
    * SOX10 upregulated in melanoma

## Gény a signalizácia špecifická pre cSCC
* **The core cSCC genes**: enriched for immunological process GO terms
    * T-cell mediated cytotoxicity and antigen processing
* **Healthy signatures**: enriched for homeostatic processes
    * including "establishment of skin barrier" with genes like CLDN1, IL18, KLF4, KRT1, NFKBIZ, and TP63, suggesting potential loss of normal balance between proliferation and differentiation and skin integrity in cSCC.

* Distinct gene signatures differentiated cancer cSCC from normal KC at single cell resolution
    *  Enriched pathways: extracellular matrix (ECM) remodeling (MMP1, MMP3, MMP10, MMP12, MMP13, SERPINB3, SERPINB4, SERPINB13, SERPINE2)
    * Differentiation markers: SOX2, EOMES, DOK6, WNT5A.AS1, INHBA, S100A2, S100A7, S100A8, S100A9
    * Inflammatory/IL-17 pathway components (MMPs, S100s) → strong inflammatory signature


## Potvrdené signatúry rakovinových buniek cSCC
Confirmed cSCC cancer cell signatures by spatial multiomics
* **Consistently upregulated genes** across scRNAseq + Visium + CosMX + Xenium: SOX2, LAMP3, CXCL10, CXCL9, CCL5, UBE2C
    * **SOX2** → absent in normal epithelium; essential for cancer-initiating cells in cSCC
    * **CXCL10, CXCL9, CCL5** → tumor progression, T-cell infiltration, immune balance (upregulated in cSCC)
    * **LAMP3** → mature dendritic cells marker, antigen processing and T cell activation
    * **UBE2C** → cell cycle regulation, cell division

## Priestorové mapovanie (Spatial mapping) (GeoMX, Visium, CosMX)
* cSCC: high proportion of T cells (CD4+, CD8+, Treg) in immune regions
* Consistent spatial alignment between molecular signatures, histology, and spatial transcriptomics
* CosMX enables subcellular RNA localization (e.g., S100A8, KRT17 in KC cancer cells)

